Ray Co., Ltd. (228670.KQ)

KRW 7690.0

(4.2%)

EBITDA Summary of Ray Co., Ltd.

Ray Co., Ltd.'s latest annual EBITDA in 2023 was 7.62 Billion KRW , down -34.54% from previous year.
Ray Co., Ltd.'s latest quarterly EBITDA in 2024 Q2 was -16.66 Billion KRW , down -491.38% from previous quarter.
Ray Co., Ltd. reported an annual EBITDA of 22.13 Billion KRW in 2022, up 150.48% from previous year.
Ray Co., Ltd. reported an annual EBITDA of 9.09 Billion KRW in 2021, down -1.38% from previous year.
Ray Co., Ltd. reported a quarterly EBITDA of -16.66 Billion KRW for 2024 Q2, down -491.38% from previous quarter.
Ray Co., Ltd. reported a quarterly EBITDA of 6.34 Billion KRW for 2023 Q3, up 18.13% from previous quarter.

Annual EBITDA Chart of Ray Co., Ltd. (2023 - 2017)

Historical Annual EBITDA of Ray Co., Ltd. (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	7.62 Billion KRW	-34.54%
2022	22.13 Billion KRW	150.48%
2021	9.09 Billion KRW	-1.38%
2020	8.95 Billion KRW	-41.21%
2019	15.23 Billion KRW	115.66%
2018	7.36 Billion KRW	159.26%
2017	1.9 Billion KRW	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-4.6 Billion KRW	39.69%
2024 Q2	-16.66 Billion KRW	-491.38%
2023 Q3	6.34 Billion KRW	18.13%
2023 Q4	5.19 Billion KRW	-18.1%
2023 FY	- KRW	-34.54%
2023 Q2	5.36 Billion KRW	322.26%
2023 Q1	-2.41 Billion KRW	-121.24%
2022 Q2	4.6 Billion KRW	1552.59%
2022 FY	- KRW	150.48%
2022 Q4	11.37 Billion KRW	93.44%
2022 Q3	5.87 Billion KRW	27.66%
2022 Q1	278.62 Million KRW	105.75%
2021 FY	- KRW	-1.38%
2021 Q4	-4.84 Billion KRW	-183.2%
2021 Q3	5.82 Billion KRW	0.0%
2020 FY	- KRW	-41.21%
2019 FY	- KRW	115.66%
2018 FY	- KRW	159.26%
2017 FY	- KRW	0.0%

Peer EBITDA Comparison of Ray Co., Ltd.

Name	EBITDA	EBITDA Difference
Osang Healthcare Co.,Ltd	157.89 Billion KRW	95.171%
InBody Co.,Ltd	44.25 Billion KRW	82.773%
Curexo Inc.	-2.75 Billion KRW	376.876%
Seegene, Inc.	35.65 Billion KRW	78.617%
i-SENS, Inc.	24.14 Billion KRW	68.423%
Gencurix Inc.	-18.09 Billion KRW	142.139%
Sugentech Inc.	-12.13 Billion KRW	162.846%
L&C Bio Co., Ltd	13.4 Billion KRW	43.113%